Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 plus irinotecan versus regorafenib or TAS-102 in previously treated metastatic colorectal cancer
NL-OMON47325Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jun 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of guadecitabine, irinotecan, regorafenib and trifluridine + tipiracil in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Vrije University Medical Center. Primary endpoints: Phase I safety and tolerability and Phase II progression-free survival. Started Jun 2014; status: active, not recruiting.
02
Drugs
guadecitabineirinotecanregorafenibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON47325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47325.